Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Viren Mehta
How Warren Buffett's company Berkshire Hathaway, Amazon and JPMorgan will address the challenge of creating affordable, quality healthcare for their employees in the US is far from clear, but they are intent on trying. Viren Mehta, founding partner of Mehta Partners LLC, considers what approach they might take to succeed where others have failed, and how such a course would impact on the pharma sector.
Data and intelligence will drive revolutionary changes in healthcare, and today's power brokers will need to adapt. Viren Mehta, founding partner of Mehta Partners LLC, considers how business consolidation in the complex US pharma market reflects the race to tap as yet under-exploited data troves, and how the resulting exploitation of those data may benefit a broader set of stakeholders.
Pharmacy Benefit Managers are a key part of the medicines market in the US, but their role is complex. Viren Mehta, founding partner of Mehta Partners, LLC considers how their business model has evolved over the years, where it is headed, and how PBMs impact others in the healthcare ecosystem.
What will the healthcare industry look like over the next generation – and what role should biopharma industry managers imagine for their sustainable success? Viren Mehta, founding partner of Mehta Partners, LLC, explores the challenges for pharma companies.
Shame has historically been used as an effective tool in bringing about a change in pricing policy within an industry. But could it be wielded against the pharma industry today? Viren Mehta, founding partner of Mehta Partners, LLC, considers.
Viren Mehta, founder of Mehta Partners, LLC, considers the oft-repeated statement that the cost of drugs represents only 10% of US healthcare expenditure. Does it matter that the figure excludes a large and growing segment of medicine spending?